Iodine (potassium iodide, kelp) trials recruiting now
6 registrations that name iodine as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 6 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 6 registrations
RecruitingNCT06734611
Folic Acid Salt Study (FISFA Zambia)
No phase
University of Alabama at Birmingham
About 250 people
Started Apr 10, 2026
In plain words A study of iodine in female participants 18 to 45, run by University of Alabama at Birmingham. It plans to enroll about 250 people at 2 sites, 1 of them in the US.
Live alone or with a partner if they can be compliant and not share the study salt.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Fortified Iodized Salt with Folic Acid (FISFA)
Registered summary
Question: How effective is fortified iodized salt with folic acid (FISFA) in increasing serum and red blood cell folate in non-lactating, non-pregnant women of reproductive age in the country of Zambia who do not have active food fortification with a folic acid program? Participants will: * Consume salt with folic acid instead of their regular salt for 6 months * Have a blood draw 4 times * Fill out surveys
Where, as registered
1 US site in 1 state; also Zambia (1).
RecruitingNCT06623500
Iodine Nutrition Status and Clinical Characteristics of Thyroid Cancer
Observational
Shandong Provincial Hospital
About 1,600 people
Started Jan 1, 2012
In plain words An observational study of iodine in people 18 to 65, run by Shandong Provincial Hospital. It plans to enroll about 1,600 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Thyroid Cancer.
Age range: 18~65 years old, gender not limited;
Living in the selected region for at least 5 years;
Patients who underwent thyroid surgery at various research centers were pathologically diagnosed with thyroid cancer;
The clinical data （general information、surgical scope 、pathological report、utrasonic report, etc ）of the case is complete.
The exclusion criteria are on the listing.
What it tests, as registered
Iodine excess; Iodine suitable
Registered summary
The effect of iodine nutritional status on thyroid cancer has been controversial for many years. We designed a prospective cohort study that recruiting patients in different iodine areas who underwent thyroid cancer surgery in branch hospitals from 2012 to 2019，and follow up their clinical outcomes. We aimed to analyse the relationship between regional iodine nutrition level and pathological types, clinical features, and prognosis of thyroid cancer.
Where, as registered
No US site; China (1).
Not yet recruitingNCT06626581
Iodine Status and Characteristics of Papillary Thyroid Cancer
Observational
Shandong Provincial Hospital
About 600 people
Starts Nov 1, 2024 (estimated)
In plain words An observational study of iodine in people 18 to 65, run by Shandong Provincial Hospital. It plans to enroll about 600 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Papillary Thyroid Carcinoma.
Age range: 18~65 years old, gender not limited;
Living in the residential area for at least 5 years;
Patients diagnosed clinically with thyroid cancer and scheduled for thyroid surgery, with pathological diagnosis of papillary thyroid cancer;
Complete clinical data: including general information, relevant laboratory tests, pathological reports, surgical reports, ultrasound reports, etc.
The exclusion criteria are on the listing.
What it tests, as registered
Iodine excess; Iodine suitable
Registered summary
The effect of iodine on papillary thyroid cancer has been controversial for many years. The investigators designed a cross-sectional study and aimed to explore the relationship between the serum and urine iodine levels and the clinical and molecular characteristics of papillary thyroid cancer.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06540469
Iodine Supplementation in Graves' Hyperthyroidism
No phase
Shandong Provincial Hospital
About 315 people
Starts Aug 1, 2024 (estimated)
In plain words A study of iodine in people 18 to 70, run by Shandong Provincial Hospital. It plans to enroll about 315 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Graves Disease; Hyperthyroidism.
patients newly diagnosed with Graves' hyperthyroidism and not treated; or
patients diagnosed with Graves' hyperthyroidism and treated with ATDs regularly less than 3 months, serum TSH is measured below normal reference range, serum FT3 or FT4 or both are measured above normal reference range and serum TRAb is…
patients diagnosed with Graves' hyperthyroidism and not regularly treated with ATDs more than 3 months, serum TSH is measured below normal reference range, serum FT3 or FT4 or both are measured above normal reference range and serum TRAb…
The exclusion criteria are on the listing.
What it tests, as registered
Iodine Supplementation in Whole Course of Treatment with ATDs; Iodine Supplementation During Maintenance Treatment with ATDs; Iodine Restriction in Whole Course of Treatment with ATDs; anti-Thyroid Drugs
Registered summary
In China, the morbidity of thyroid diseases is high and the harm is serious. Iodine is closely related to thyroid diseases. It should be paid attention to guide patients to supplement iodine scientifically. Thyroid iodine uptake in hyperthyroidism patients is enhanced, and patients are generally advised to limit iodine intake in clinical practice. However, recent studies suggest that there is no definite conclusion on whether patients with hyperthyroidism should strictly limit iodine intake. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06721273
Iodine Supplementation and Fertility Parameters
No phase
Tehran University of Medical Sciences
About 230 people
Starts Mar 1, 2025 (estimated)
In plain words A study of iodine in female participants 18 to 45, run by Tehran University of Medical Sciences. It plans to enroll about 230 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 45. Conditions: Infertility (IVF Patients).
Women with diminished ovarian reserve
Willingness to participate
Age range: 18 to 45 years
Women with a menstrual cycle of 21 to 42 days
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Iodine; Placebo
Registered summary
Iodine has been identified as a potential factor influencing female fertility during the childbearing years. The American Thyroid Association recommends that women attempting to conceive take a supplement containing 150 µg of iodine. However, no clinical trials have specifically examined the necessity of iodine supplementation in women experiencing infertility. Furthermore, no information is available on the optimal dose and duration of iodine supplementation to increase the chances of successful treatment in this group of women. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07185958
Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy
Observational
Aalborg University Hospital
About 80 people
Starts Sep 22, 2025 (estimated)
In plain words An observational study of iodine in people 18 and older, run by Aalborg University Hospital. It plans to enroll about 80 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Brain Metastases; Bone Metastases; Head and Neck Cancer; Lung Cancer.
ECOG performance status (PS) 0-2
Assessed to be able to complete the protocol scanning regime
Referred for RT
For head and neck cancer patients, a PET/CT scan must have been performed during the diagnostic evaluation for cancer
1 more inclusion criterion and the exclusion criteria are on the listing.
The primary aim of this clinical study, 'Dual Energy CT - a tool for delineation of tumor and organs at risk in radiotherapy' (DART) is to evaluate whether dual-energy CT (DECT) is at least as effective as magnetic resonance imaging (MRI) in delineating both tumors and organs at risk (OARs) in patients referred for radiotherapy (RT). The full summary is on the listing.